Engineer In-Vitro Marketing 
Pharmaceutical Technology
SEPTEMBER 22, 2022
According to the partnership, Celltrion will oversee the development of ABP 102, after Abpro concludes in vitro studies, as well as hold the global marketing rights. To create these antibodies, the platform merges next-generation sequencing, nano-immunology, superior engineering and bioinformatics.
FDA Law Blog
FEBRUARY 19, 2024
Loloei tackled legal matters related to various aspects of the regulation of medical devices, in vitro diagnostics, and combination products including regulatory and compliance issues, dispute resolutions between the FDA and sponsors, and FDA enforcement actions. While at FDA, Ms. During her FDA tenure, Ms. Gibbs , HP&M Director.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
AUGUST 8, 2024
Tecelra is the first cell therapy engineered for a solid tumor cancer in the US, offering a new option for patients with specific genetic markers who have previously undergone chemotherapy. It is also the first new treatment for adults with synovial sarcoma in over a decade. The trial showed a 43 percent response rate with 4.5
pharmaphorum
FEBRUARY 13, 2022
Quris’ BioAI safety prediction platform – which is based on human tissue samples on chips, nanosensors and machine learning – will be compared to traditional in vitro and in vivo laboratory techniques for spotting toxicity. The post Merck will assess Quris’ AI ‘patient-on-a-chip’ drug safety appeared first on.
pharmaphorum
DECEMBER 1, 2022
Exploring the implementation of complex in-vitro models for drug development. 3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years, with the global 3D Cell Culture market predicted to reach a value of $3.48 Billion by 2028. Billion by 2028. Event Hashtag: #3DCellCulture2023. Who Should Attend?
Pharmaceutical Technology
FEBRUARY 28, 2023
It was engineered with an Fc-silent IgG1 isotype to avoid activation of Fc-receptor-mediated non-specific immune. The bispecific antibody was found to conditionally activate the immune pathway in the tumour microenvironment in vitro and in vivo trials. Topic sponsors are not involved in the creation of editorial content.
Pharmaceutical Technology
JANUARY 6, 2023
It requires having access to proper techniques and skill sets, state-of-the-art equipment, process scientists and engineers who have a deep understanding of Quality by Design (QbD) principles, and methods for product and process characterisation. In vitro release testing to demonstrate bioequivalence. Simplicity matters.
Expert insights. Personalized for you.
130 
Let's personalize your content